Search
TRC093
go.drugbank.com/drugs/DB06356InvestigationalTRC093 is a recombinant humanized IgG1k monoclonal antibody.
Bambermycins
go.drugbank.com/drugs/DB11377ExperimentalVet approvedThey are used as an additive in food ingested by chickens and swine. The bambermycin complex of antibiotics consists primarily of moenomycins A and C.
Pentazocine
go.drugbank.com/drugs/DB00652ApprovedVet approvedIt is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Pivmecillinam
go.drugbank.com/drugs/DB01605ApprovedInvestigationalPivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa.
Emodepside
go.drugbank.com/drugs/DB11403InvestigationalVet approvedEmodepside is an anthelmintic drug that is effective against a number of gastrointestinal nematodes, is licensed for use in cats and belongs to the class of drugs known as the octadepsipeptides, a relatively
Biapenem
go.drugbank.com/drugs/DB13028InvestigationalBiapenem has been used in trials studying the treatment of various bacterial infections. … It is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008]
RO7300490
go.drugbank.com/drugs/DB17535InvestigationalRO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in … RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist.
RGN6024
go.drugbank.com/drugs/DB33059ExperimentalReglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug. … cells, and suppresses tumor growth in glioblastoma xenograft models.
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalCoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer.